Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > FDAnews Drug Daily Bulletin > Novartis to Add Warnings to Rasilez Blood-Pressure Drug

FDAnews Drug Daily Bulletin

Feb. 20, 2012 | Vol. 9 No. 35

Novartis to Add Warnings to Rasilez Blood-Pressure Drug

Novartis AG said it will add a warning to the label for its blood-pressure drug Rasilez in Europe to comply with a request from regulators.
Bloomberg

Register Now
Print This Page
Email This Article
RSS
Archives

Related Articles

Mylan Launches Generic Tricor Tablets Is the FDA Approving too Many Drugs Starting with X and Z?Court Rejects Merck Deal Over Vioxx Citizens in Poor EU States Can’t Afford Medicines, Health Promoters Say

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.